INCA-Pharm Srl , founded in 2006, is a subsidiary of CARINOPHARM GmbH , a German company specializing in the marketing of injectable medicines for hospital use. The company, with headquarters and offices in Frosinone, currently distributes PERFAN® (enoximone) in Italy , a medicine marketed in the main European countries and used for twenty years in the vast majority of cardiac surgery and cardiac surgery intensive care departments of hospitals and nursing homes. Italian care. Furthermore, since December 2012, INCA-Pharm has been marketing URASAP® , the only equivalent medicine based on urapidilavailable on the Italian market. URASAP® , administered intravenously, is indicated in the treatment of hypertensive emergencies. Thanks to the commitment of its Scientific Service and the support of the parent company, the company provides the necessary medical-scientific information on its products to hospital health professionals. INCA-Pharm is actively involved in expanding its range to include other drugs for hospitalized patients undergoing intensive care. legal notes | privacy This website and the information contained therein are for the exclusive use of residents in Italy. Countries other than Italy may have different regulatory requirements, data requirements or medical practices that differ from Italy, and therefore this information may be inappropriate for use outside Italy. The contents of the site are intended as purely informative, and do not in any way replace discussions with the company. If you have any questions about this site please contact INCA-Pharm. November 2010 PERFAN®: information brochure available The "Information Brochure for Healthcare Personnel" has been published, full of useful information on PERFAN® (enoximone). The brochure was distributed to healthcare professionals in the congress setting. Settembre 2011Seminario dell'Università di Roma "Tor Vergata" "Impaired Left Ventricular Function: Perioperative Management" è il titolo del Seminario della Scuola di Specializzazione di Cardiochirurgia dell'Università di Roma "Tor Vergata" svoltosi lo scorso 12 settembre. Novembre 2011"Enoximone in the clinical daily routine" A cura dei D.ri A. Wiebalck e Birgit Frohn, è stata pubblicata la monografia "Enoximone in the clinical daily routine" edita da Verlag, Berlino. Febbraio 2012Nuovi prodotti per INCA-Pharm A seguito dell'opinione positiva delle Agenzie Regolatorie Europee coinvolte nelle rispettive procedure registrative, verranno presto rilasciate le Autorizzazioni all'Immissione in Commercio di due nuovi medicinali. Febbraio 2012La scelta costo-efficace "PERFAN®: la scelta costo-efficace nell'insufficienza cardiaca acuta" è il nuovo visual realizzato da INCA-Pharm destinato agli specialisti e ai farmacisti ospedalieri. Dicembre 2012URASAP® disponibile sul mercato ospedaliero INCA-Pharm ha lanciato il medicinale ad uso ospedaliero URASAP®, primo farmaco equivalente a base di urapidil. © Copyright 2012 - 2016 INCA-Pharm S.r.l. [ P. Iva 02452050608 | n. REA 153261 ] | info[at]inca-pharm.it | designed by: atweb